Upgrade to SI Premium - Free Trial

Morgan Stanley on Biogen (BIIB) Acquisition of Hi-Bio

May 22, 2024 9:25 AM

Morgan Stanley analyst Matthew Harrison reiterated an Overweight rating and $331.00 price target on Biogen (NASDAQ: BIIB)

For an analyst ratings summary and ratings history on Biogen click here. For more ratings news on Biogen click here.

Shares of Biogen closed at $227.69 yesterday.


Analyst Comments

Next Articles